Pricing Log in Create free account

Mesoblast Limited (MESO) vs Palvella Therapeutics, Inc. (PVLA)

Mesoblast Limited and Palvella Therapeutics, Inc. are both Biotechnology companies. Mesoblast Limited and Palvella Therapeutics, Inc. are of similar size ($1.8B and $1.8B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 146.7% against −26.5%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −1,091.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Palvella Therapeutics, Inc. leads on 11 and Mesoblast Limited on 5.

Valuation

Metric MESO PVLA Biotechnology median
P/E n/m n/m 8.50
P/S 137.69 41.55 9.71
P/B 1.80 7.96 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 137.28 35.55 9.21
Earnings yield (8.43%) (4.01%) (33.15%)
Free cash flow yield (8.17%) (1.86%) (25.50%)

Profitability

Metric MESO PVLA Biotechnology median
Gross margin (269.72%) 100.00% 65.16%
Operating margin (826.28%) 0.00% 0.00%
Net margin (1,091.71%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (46.63%) (56.36%)
Return on assets 0.00% (37.70%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MESO PVLA Biotechnology median
Revenue growth (TTM) (26.54%) 146.67% 6.02%
EPS growth (last fiscal year) 48.24% 52.62% 30.26%
Revenue growth, 5-year CAGR 74.39% 8.03% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO PVLA Biotechnology median
Debt to equity 0.22 0.00 0.00
Current ratio 1.58 21.18 4.72
Net debt to EBITDA (0.67) 1.50 0.96

Dividend

Metric MESO PVLA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MESO PVLA Biotechnology median
Market cap 1.81b 1.83b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack